Mechanism
Amylin analogues
Amylin is a pancreatic hormone released together with insulin that induces satiety. It acts through amylin receptors, which form when the calcitonin receptor pairs with a receptor activity-modifying protein (RAMP). Amylin analogues are lipidated, stabilised versions designed to last longer and to avoid native amylin's tendency to form amyloid. In rodents they reduced food intake and body weight, and several are in human trials alone or combined with incretin drugs.
How the members differ
- Cagrilintide is a non-selective agonist of the AMY1, AMY2 and AMY3 receptors and the calcitonin receptor, and has been studied alone and combined with semaglutide.
- Eloralintide preferentially activates the AMY1 receptor over the calcitonin receptor in human receptor assays, and caused less conditioned taste avoidance than cagrilintide in lean rats.
- Amycretin is a single molecule with a GLP-1 receptor portion and an amylin receptor portion joined by a linker, studied as both an oral tablet and an injection.
Compounds in this group
CagrilintideHuman trial evidence · InvestigationalCagrilintide is an investigational long-acting, lipidated analogue of the pancreatic hormone amylin that acts at amylin and calcitonin receptors and is given by once-weekly subcutaneous injection in clinical trials. It has been studied alone in a phase 2 weight-management trial and, most extensively, in combination with semaglutide (CagriSema) in phase 3 trials, with gastrointestinal events the most commonly reported adverse events. It is not approved by the FDA, and this entry summarizes published and registered trials for research reference only.
EloralintideHuman trial evidence · InvestigationalEloralintide (LY3841136) is an investigational once-weekly peptide that selectively activates amylin receptors. It has been studied in phase 1 and phase 2 randomized trials in adults with obesity or overweight, and phase 3 trials are registered. It is not an approved medicine, and this entry is for research information only.
AmycretinHuman trial evidence · InvestigationalAmycretin (now also called zenagamtide) is an investigational single-molecule peptide that activates both GLP-1 and amylin receptors. It has been studied in subcutaneous and oral forms in phase 1 and phase 2 randomized trials, and phase 3 trials are registered. It is not an approved medicine, and this entry is for research information only.
PramlintideHuman trial evidence · Approved, no longer marketedPramlintide is a synthetic 37-amino-acid analog of human amylin, FDA-approved in 2005 as Symlin for adjunctive use with mealtime insulin in type 1 and type 2 diabetes; Drugs@FDA now lists all Symlin products as discontinued.
Compare Cagrilintide, Eloralintide, Amycretin side by side
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. Mechanism descriptions summarize published research and are not claims of effect in people.